Roborock Saros Z70 vs Roborock Saros 10R: which robot vacuum is best?
The Roborock Saros Z70 is the latest robot vacuum from the company, offering not just impressive vacuuming and mopping skills, but also a robotic arm. This can pick up items left on your floor, allowing it to provide you with a more comprehensive clean. However, our Roborock Saros Z70 review found it to be somewhat underwhelming. Meanwhile, the older Roborock Saros 10R offers many of the same features as the Z70 — minus the wild price tag and robotic arm.
So, which one makes a better robot vacuum for your home? The Roborock Saros Z70 or Roborock Saros 10R? Is the robotic arm worth the extra money, or can you save several hundred bucks by opting for the Saros 10R? Here's a closer look at these two robot vacuums to help you decide which one to buy.
Recommended Videos
Pricing and design
The Roborock Saros Z70 carries the eye-watering price of $2,600, though it can often be found on sale for much less. Its size is fairly standard for robot vacuums, with a rectangular base and circular robot. There are a few unique accents throughout the dock and the robot, giving it a more premium appearance than most competitors. Of course, there's also the robotic arm. This is typically stowed away in a small chamber on top of the robot. Only when an object is detected will it deploy.
The Saros 10R looks very similar to the Z70, though it's missing some of the accents and fancy flourishes of the Z70. It still looks fantastic, however, and much of the designs are shared across the two products. The 10R is also much more affordable at $1,600, though it's still one of the most expensive robots on the market.
Winner: Roborock Saros 10R
Vacuuming
Vacuuming performance is quite similar between these two devices. The Saros Z70 has the better suction numbers at 22,000 Pa, but the 10R is no slouch at 20,000 Pa. Both can also swing out their side brush to reach tight corners, can automatically detach their mopping pads to ensure your carpets stay dry, and use the same Starsight Autonomous System 2.0 for navigation. In testing, both were more than capable of dealing with daily messes, and they left behind nice tidy patterns that give your home a 'just cleaned' feeling.
Obstacle avoidance was excellent for both robots, and the ability to lift their chassis to cross thresholds or deal with different types of environments made them versatile companions for all sorts of carpet. Both also feature an anti-tangle system that never once needed any manual intervention, as hair and long fibers were deftly removed and suctioned away into its dustbin.
In short — both are excellent vacuums. The Saros Z70 might have the upper hand when it comes to total suction, but real-world testing revealed two robots that are just about evenly matched.
Winner: Tie
Mopping
It's a similar story for mopping. Roborock has equipped these two devices with essentially the same mopping systems. They feature two spinning mopping pads, one of which can swing outward to clean near baseboards. Both robots will lift their mops when traveling on carpet and give themselves a self-cleaning when back at the docking station. This includes a hot water rinse followed by an air dry — which goes a long way towards eliminating the mold and mildew smell found on lesser robots.
Testing once again found them to be perfectly matched for daily cleaning chores. Spills and stains were easily removed by the Z70 and 10R, and their ability to leave behind their mops when vacuuming is another huge win.
Winner: Tie
Additional features
Most additional features are shared by the Saros Z70 and Saros 10R. This includes:
Intelligent dirt detection
Auto detergent dispensing
Auto tank refilling
Auto dust emptying
Auto brush lifting
Adaptive route algorithm
App support
Voice assistant
The big difference, of course, is the robotic arm of the Saros Z70. But based on our testing, it's not quite ready for the spotlight. It will almost never detect objects it can pick up when they're placed on carpet, relegating it to only being useful on hard floors.
Even then, the arm has a difficult time gripping certain objects, and it takes a very long time to operate. A weight restriction of 300 grams limits what it can handle, and it's not uncommon for it to take multiple attempts to pick up and properly move an object to the designated spot in your house. It's a great first step — but like any innovative new technology, it still needs some time in the oven.
Winner: Tie
Verdict
Despite lending a robotic arm to your home, the Roborock Saros Z70 isn't the best fit for most shoppers. Instead, consider picking up the Roborock Saros 10R. It packs in nearly all the same features — minus the arm — and it's much more affordable. Capable of providing you with a superior floor cleaning experience, it's one of the best robot vacuums on the market. Be sure to also compare the Saros 10R and Saros 10, and they're both great products but they go about mopping in entirely different ways.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
37 minutes ago
- Yahoo
Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Dan Ives' new artificial intelligence exchange-traded fund (ETF) holds securities beyond the Magnificent 7 stocks, as he believes in looking past valuations for investments in the technology sector. What Happened: The Dan IVES Wedbush AI Revolution ETF (NYSE:IVES), managed by the Wedbush analyst, started trading on June 4, earlier this month. Ives boasts of the fund by saying that it just doesn't have the top four, five Magnificent 7 names, but stocks which investors wouldn't even thematically consider as an AI name today. "I believe the market is still massively underestimating what the growth is going to look like for the AI revolution in tech," he told CNBC. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — According to him, tech trade remains significant even for the investors who missed out on its growth in the past few years. "If you focus just on valuation, you miss every transformational tech stock of the last 20 years," Ives said. Ives says Oracle Corp. (NYSE:ORCL) will be the 'epicenter' of the AI theme, while highlighting other 'AI 30' stocks which are part of his fund. Palantir Technologies Inc. (NASDAQ:PLTR), International Business Machines Corp. (NYSE:IBM), Salesforce Inc. (NYSE:CRM), SoundHound AI Inc. (NASDAQ:SOUN), and Innodata Inc. (NASDAQ:INOD) are a few notable names that are a part of his ETF's 'AI 30' basket. Microsoft Corp. (NASDAQ:MSFT), Nvidia Corp. (NASDAQ:NVDA), and Broadcom Inc. (NASDAQ:AVGO) are the top three holdings of the IVES It Matters: The 'AI 30' stocks, which are a part of the IVES ETF, hold the AI plays from multiple industries. They include hyperscalers, cybersecurity, consumer platforms, and robotics. According to Ives, the list was compiled from his deep dives into major AI players. The ETF has $183 million in assets under management as of June 17 close. Ives said that the AI space was experiencing a "golden age." The Dan IVES Wedbush AI Revolution ETF has risen by 2.76% since its inception. A comparable index, S&P Kensho Global Artificial Intelligence Enablers, rose 6.08% on a month-to-date basis. Meanwhile, the SPDR S&P 500 ETF Trust (NYSE:SPY) and Invesco QQQ Trust ETF (NASDAQ:QQQ), which track the S&P 500 index and Nasdaq 100 index, respectively, declined slightly on Wednesday. The SPY was down 0.015% at $597.44, while the QQQ was 0.017% lower at $528.99, according to Benzinga Pro data. Read Next: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Photo courtesy: Shutterstock This article Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7 originally appeared on
Forbes
38 minutes ago
- Forbes
Google's Quiet Confirmation Of The Pixel 10
Google's "Talking Phones Podcast" title card Google is having a little bit of fun in its latest iPhone vs Pixel video. While the Pixel 9 Pro takes pride of place, there's also a surprising cameo for what comes next… the Pixel 10. The Pixel 10 Easter Egg The details come at the end of Google's latest promotional video posted on its Made By Google YouTube channel. In it, an iPhone and a Pixel talk about the recent advances made by Apple's smartphone, with a not at all surprised Pixel noting when that feature arrived on Pixel and Android. These include live translation, hold assistance and call screening arriving four, five and seven years ago respectively., Of course, the capabilities of all these features have improved significantly over the last few years, so there are shades of Oranges to (ahem) Apples here, but it makes Google's point effectively. The story of Android being ahead of iOS is here for all to hear. The little easter egg at the end is part of another story, leading into the next Pixel release. The iPhone quietly asks the Pixel 9 Pro, 'so, what are you working on for Pixel 10… just out of curiosity?' Naming The Pixel 10 It's no secret that Google is working on the next family of Pixel smartphones. Neither is it a secret that we're expecting an entry-level Pixel 10, a premium Pixel 10 Pro, a larger Pixel 10 Pro XL and an innovative Pixel 10 Pro Fold. Yet this is the first time Google has publicly acknowledged that the new handsets will carry the Pixel 10 branding. Although the sharp-eared watchers will note that it was the iPhone confirming the new Pixel 10, not the Pixel 9 Pro. So, did Apple confirm the new name, rather than Google? Google is expected to announce the Pixel 10 family at an upcoming Made By Google event. While dates have not been confirmed, talk within the community picks out Wednesday, Aug. 20 for the launch, and Thursday, Aug 28. for the first handsets to go on sale to the public. Now read how the Pixel 10 will impact every Android smartphone in 2025 and beyond…
